We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other Wednesday’s best-performing stocks.
The stock market rebounded on Wednesday, with all major indices ending in the green as investors cheered the Federal Reserve’s decision to keep interest rates unchanged.
On Wednesday afternoon, the Fed kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still “wait and see” the impact of President Donald Trump’s tariff policies.
The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent.
Beyond the major indices, 10 firms stood out with strong gains, thanks to a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Wednesday’s 10 best-performing stocks and detail the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
A pharmaceutical sales rep holding a medicine pack, highlighting the drug candidate products.
Tempus AI saw its share prices increase by 12.59 percent on Wednesday to finish at $58.76 apiece as investors loaded portfolios following an optimistic outlook guidance, offsetting a dismal earnings performance during the past quarter.
In its latest earnings release, Tempus AI, Inc. (NASDAQ:TEM) said that it is targeting $1.25 billion in revenues for the consolidated Tempus and Ambry Genetics for full-year 2025, which would represent an 80 percent growth year-on-year.
During the first quarter, Tempus AI, Inc. (NASDAQ:TEM) widened its net loss by 5.1 percent to $68 million from $64.7 million in the same period last year.
Revenues, however, were higher by 75.86 percent to $255 million from $145.8 million, with Genomics contributing $193.8 million, or an 88.9 percent increased contribution year-on-year.
“The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage,” said Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky.
“Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos,” he added.
